My Appeal Of PD0325901

All patients received low dose steroids (0��5?mg/kg/d) during induction therapy. Management of DS consisted of prompt discontinuation of ATRA and administration of i.v. dexamethasone (10?mg every 12?h for a minimum of 4?d or until complete resolution of DS manifestations. Haematological CR was defined as the presence of normal bone marrow http://www.selleckchem.com/products/3-methyladenine.html (BM) cellularity with absence of leukaemic promyelocytes, with peripheral blood polymorphonuclear (PMN) and platelet counts >1?��?109/l and >100?��?109/l, respectively. Resistant disease was defined as persistence in the BM of leukaemic promyelocytes after 90?d of ATRA treatment. Molecular remission was defined as reported elsewhere (Lo Coco et?al, 1999). BM aspirates were obtained at diagnosis, at haematological CR, at the end of consolidation therapy, every 6?months during the maintenance phase and after the end of treatment. Following isolation of the BM mononuclear fraction by centrifugation on a Ficoll-Hypaque gradient, cells were washed twice in phosphat-buffered saline, suspended in a 4?mol/l guanidium thiocyanate solution, stored at ?20��C and shipped in dry ice to the http://www.selleckchem.com/products/PD-0325901.html reference laboratory (University ��La Sapienza�� of Rome, Italy) for centralized molecular studies. Total RNA was extracted by the method of Chomczynsky and Sacchi (1987). Prior to RT-PCR analysis, RNA integrity was assessed by running samples on a formaldehyde minigel. The protocol and the oligonucleotide primers used for RT-PCR of the PML-RARA hybrid gene have been reported elsewhere (Diverio et?al, 1996). Amplification of PML-RARA was carried out, in all cases, simultaneously with the amplification of the ABL1 gene as an internal control. Differences in the distribution of individual parameters in subsets were assessed by nonparametric tests, at a significance level of P? http://www.selleck.cn/products/Cisplatin.html responders. As a consequence, OS was calculated from both the diagnosis and the date of achievement of CR to death due to any cause, or to the date of last follow-up for patients alive (censored). DFS was calculated from achievement of CR to relapse or death in CR, or to the date of last follow-up for patients alive in first CR (censored). Cumulative incidence of relapse (CIR) was calculated from CR to relapse or to the date of last follow-up for patients alive in first CR (censored), using the cumulative incidence method, where death in CR was considered as a competing risk. Cumulative incidence of non-relapse mortality (CINRM) was calculated from CR to death in CR or to the date of last follow-up for patients alive in first CR (censored), using the cumulative incidence method where relapse was considered as a competing risk. The outcomes for OS, DFS, CIR and CINRM were truncated after a 5-year period of follow-up, in order to avoid their underestimation due to under-reporting from participating centres.